Provided By GlobeNewswire
Last update: Feb 20, 2025
Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales
Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion
Read more at globenewswire.com